Social Anxiety Disorder Clinical Trial
Official title:
A Randomized Controlled Trial of the Effectiveness of Breathing Focused Yoga (BFY) in Improving Symptoms of Social Anxiety Disorder
Verified date | September 2016 |
Source | Centre for Addiction and Mental Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this study is to determine the safety and effectiveness of Breathing Focused Yoga (BFY) in improving symptoms of social anxiety disorder (SAD). Patients with SAD will be randomized to 8 weeks of yoga or 8 weeks of wait-list. Symptom severity and quality of life will be compared between the two groups before and after the 8 weeks.
Status | Completed |
Enrollment | 60 |
Est. completion date | January 30, 2017 |
Est. primary completion date | January 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: 1. Male or female patients aged 18-65 years 2. Primary diagnosis of SAD, per the DSM-IV-TR (APA, 2000) 3. LSAS score of =50 4. Absence of serious medical illness 5. Not on any psychotropic medications currently, or on stable medications for at least 8 weeks prior to starting treatment 6. Short-acting benzodiazepines (e.g. lorazepam 1 mg prn) and sleep medications (e.g. zopiclone 7.5 mg prn) may be used, but not within 12 hours prior to a study visit Exclusion Criteria: 1. Current primary diagnosis of major depressive episode, mania or psychosis 2. A score of =15 on the first 17 items of the HAM-D at Screening or Baseline 3. Diagnosis of a substance abuse disorder within the prior 6 months 4. Presence of medical or mental health conditions that would inhibit the patient's ability to participate in the study 5. Currently receiving any structured formal psychotherapy (supportive therapy is allowed) |
Country | Name | City | State |
---|---|---|---|
Canada | Centre for Addition and Mental Health | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
Centre for Addiction and Mental Health |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Liebowitz Social Anxiety Scale (LSAS) Total Score | Baseline to study endpoint (Week 8) | ||
Secondary | Change in Clinical Global Impression Scale | Baseline to study endpoint (Week 8) | ||
Secondary | Change in Hamilton Depression Rating Scale (HAM-D) Total Score | Baseline to study endpoint (Week 8) | ||
Secondary | Change in Quality of Life Enjoyment and Satisfaction Scale (QLESQ) Total Score | Baseline to study endpoint (Week 8) | ||
Secondary | Change in Quick Inventory of Depressive Symptomatology (QIDS) Total Score | Baseline to study endpoint (Week 8) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06274112 -
Using TMS to Understand Neural Processes of Social Motivation
|
N/A | |
Completed |
NCT02554929 -
Treatment of Social Anxiety Disorder and Selective Mutism
|
N/A | |
Completed |
NCT00684541 -
Interpretation Modification Program for Social Phobia
|
N/A | |
Completed |
NCT00684320 -
Attention Disengagement Training for Social Phobia
|
N/A | |
Completed |
NCT03247075 -
Internet-delivered CBT vs Internet-delivered Support and Counseling for Youth With Social Anxiety Disorder - An RCT
|
N/A | |
Completed |
NCT02811458 -
Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders
|
N/A | |
Withdrawn |
NCT04622930 -
Waitlist-Control Trial of Smartphone CBT for Social Anxiety Disorder (SAD)
|
N/A | |
Active, not recruiting |
NCT05018312 -
Modified Collaborative Assessment VS Standard Assessment on Readiness For Psychotherapy Among Patients With Anxiety
|
N/A | |
Active, not recruiting |
NCT05124639 -
Clinical Trial of a Group Self-management Support Program for Anxiety Disorders
|
N/A | |
Completed |
NCT05858294 -
The Safety, Acceptability and Efficacy of Alena
|
N/A | |
Active, not recruiting |
NCT05600114 -
Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder
|
Phase 2 | |
Not yet recruiting |
NCT06081348 -
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
|
Phase 2 | |
Not yet recruiting |
NCT02924610 -
Brief Intervention to Reduce Fear
|
Phase 4 | |
Active, not recruiting |
NCT02592564 -
Brain Plasticity and Cellular Aging After Internet-delivered CBT for Social Anxiety Disorder
|
N/A | |
Recruiting |
NCT02305537 -
Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment
|
N/A | |
Terminated |
NCT03764644 -
Web-based Attention Bias Modification Treatment for Childhood Anxiety Disorders
|
N/A | |
Unknown status |
NCT01712321 -
Study of Vilazodone to Treat Social Anxiety Disorder
|
N/A | |
Completed |
NCT01320800 -
CBT for Social Anxiety Disorder Delivered by School Counselors
|
Phase 2 | |
Completed |
NCT00485888 -
Flushing in Social Anxiety Disorder on Cipralex
|
Phase 2 | |
Completed |
NCT00872820 -
Examining Long-Term Effects and Neural Mediators of Behavioral Treatments for Social Anxiety Disorder
|
N/A |